Ignite Creation Date:
2024-05-05 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00244439
Status:
COMPLETED
Last Update Posted:
2013-12-23
First Post:
2005-10-24
Brief Title:
Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice
Sponsor:
Taro Pharmaceuticals USA
Organization:
Taro Pharmaceuticals USA
Study Overview
Official Title:
A Multi-Center Phase III Study to Evaluate MALG a Novel Malathion 005Formulation for the Control of Head Lice in Pediatric and Adult Subjects With Pediculosis Capitis
Status:
COMPLETED
Status Verified Date:
2013-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Current treatments for head lice include over-the-counter products such as permethrin and prescription products such as OVIDE malathion 05 lotion In a previous phase II study a novel easy-to-use malathion 05 formulation was found to be a safe treatment for head lice The current study will compare the efficacy and safety of this novel formulation of malathion with OVIDE and with an over-the-counter permethrin product
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None